Pulling SEC filings + quote and writing the call…

Praxis Precision Medicines, Inc.
Next earnings Aug 3, 2026 · consensus $-3.72 EPS
Last earnings -1.4% on 2026-05-07
A pre-revenue clinical-stage biotech burning $249M a year, richly priced on trial hopes — a binary bet, not an investment.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing CNS/neurology drug candidates, and by its own description in the 10-K, 'investing in our common stock involves a high degree of risk' and 'you might lose all or part of your investment.' It has no approved products and generated $0 of revenue in FY2025 (after token $2.45M and $8.55M in the prior two years from collaboration/grant income), while net loss widened to -$303M and R&D spending jumped 75.3% to $267M as it advanced trials. The accumulated deficit is now $1.1B, and operating cash burn was -$249M for the year.
Sources: SEC EDGAR (CIK 0001689548, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/21/2026, 9:02:53 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $2.45M | $8.55M | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$167M | -$215M | -$126M | -$200M | -$326M |
| Net income | -$167M | -$214M | -$123M | -$183M | -$303M |
| Diluted EPS | -$3.94 | -$69.65 | -$18.69 | -$10.21 | -$13.48 |
| Net margin | — | — | -5037.9% | -2137.5% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1070 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-06-10 | Arbuckle Stuart A Director | Award | 1.37K | |
| 2026-06-10 | Chodakewitz Jeffrey Director | Award | 1.37K | |
| 2026-06-10 | YOUNG WILLIAM D Director | Award | 1.37K | |
| 2026-06-10 | DeSimone Jill Director | Award | 1.37K | |
| 2026-06-10 | Cudkowicz Merit Ester Director | Award | 1.37K | |
| 2026-06-10 | MITCHELL DEAN J Director | Award | 1.37K | |
| 2026-06-10 | KINDLER JEFFREY B Director | Award | 1.37K | |
| 2026-06-10 | Norden Gregory Director | Award | 1.37K |